Tissue kallikrein-modifed mesenchymal stem cells provide enhanced protection against ischemic cardiac injury after myocardial infarction

Circulation Journal

Volumn 77, Issue 8, 2013, Pages 2134-2144

  Gao, Lin ^a   Bledsoe, Grant ^b   Yin, Hang ^a   Shen, Bo ^a   Chao, Lee ^a   Chao, Julie ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b CHARLESTON SOUTHERN UNIVERSITY   (United States)

Author keywords

Angiogenesis; Apoptosis; Inflammation; Remodeling

Indexed keywords

CASPASE 3; PROTEIN KINASE B; TISSUE KALLIKREIN; VASCULOTROPIN; CASP3 PROTEIN, RAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROSIS; GENE EXPRESSION; GENETIC TRANSDUCTION; HEART FUNCTION; HEART INFARCTION; HEART INFARCTION SIZE; HEART INJURY; HEMODYNAMIC PARAMETERS; HISTOLOGY; HUMAN; HUMAN CELL; HYPERTROPHY; HYPOXIA; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; MESENCHYMAL STEM CELL; NEOVASCULARIZATION (PATHOLOGY); NEWBORN; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ADENOVIRIDAE; ANGIOGENESIS; ANIMAL; BIOSYNTHESIS; COMPLICATION; GENETICS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; METABOLISM; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; PATHOLOGY; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; ADENOVIRUS; HEART MUSCLE ISCHEMIA;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; CASPASE 3; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; NEOVASCULARIZATION, PHYSIOLOGIC; RATS; RATS, SPRAGUE-DAWLEY; TISSUE KALLIKREINS; TRANSDUCTION, GENETIC;

EID: 84880843626     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-12-1585     Document Type: Article

References (35)

1. Paul D, Samuel SM, Maulik N. Mesenchymal stem cell: Present challenges and prospective cellular cardiomyoplasty approaches for myo-cardial regeneration. Antioxid Redox Signal 2009; 11: 1841-1855.
2. Gnecchi M, He H, Liang OD, Melo LG, Morello F, Mu H, et al. Paracrine action accounts for marked protection of ischemic heart by Akt-modifed mesenchymal stem cells. Nat Med 2005; 11: 367-368.
3. Gnecchi M, He H, Noiseux N, Liang OD, Zhang L, Morello F, et al. Evidence supporting paracrine hypothesis for Akt-modifed mesen-chymal stem cell-mediated cardiac protection and functional improvement. FASEB J 2006; 20: 661-669.
4. Choi SH, Jung SY, Kwon S, Baek SH. Perspectives on stem cell therapy for cardiac regeneration. Circ J 2012; 76: 1307-1312.
5. Duan HF, Wu CT, Wu DL, Lu Y, Liu HJ, Ha XQ, et al. Treatment of myocardial ischemia with bone marrow-derived mesenchymal stem cells overexpressing hepatocyte growth factor. Mol Ther 2003; 8: 467-474.
6. Gao F, He T, Wang H, Yu S, Yi D, Liu W, et al. A promising strategy for the treatment of ischemic heart disease: Mesenchymal stem cell-mediated vascular endothelial growth factor gene transfer in rats. Can J Cardiol 2007; 23: 891-898.
7. Mangi AA, Noiseux N, Kong D, He H, Rezvani M, Ingwall JS, et al. Mesenchymal stem cells modifed with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med 2003; 9: 1195-1201.
8. Tang YL, Tang Y, Zhang YC, Qian K, Shen L, Phillips MI. Improved graft mesenchymal stem cell survival in ischemic heart with a hypox-ia-regulated heme oxygenase-1 vector. J Am Coll Cardiol 2005; 46: 1339-1350.
9. Li H, Zuo S, He Z, Yang Y, Pasha Z, Wang Y, et al. Paracrine factors released by GATA-4 overexpressed mesenchymal stem cells increase angiogenesis and cell survival. Am J Physiol Heart Circ Physiol 2010; 299: H1772-H1781.
10. Gao X, Tan Y, Wang H. Overexpression of Csx/Nkx2.5 and GATA-4 enhances the effcacy of mesenchymal stem cell transplantation after myocardial infarction. Circ J 2011; 75: 2683-2691.
11. Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: Kal-likreins, kininogens, and kininases. Pharmacol Rev 1992; 44: 1-80.
12. Lundwall A, Band V, Blaber M, Clements JA, Courty Y, Diamandis EP, et al. A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. Biol Chem 2006; 387: 637-641.
13. Agata J, Chao L, Chao J. Kallikrein gene delivery improves cardiac reserve and attenuates remodeling after myocardial infarction. Hypertension 2002; 40: 653-659.
14. Yin H, Chao L, Chao J. Kallikrein/kinin protects against myocardial apoptosis after ischemia/reperfusion via Akt-glycogen synthase ki-nase-3 and Akt-Bad.14-3-3 signaling pathways. J Biol Chem 2005; 280: 8022-8030.
15. Yao YY, Yin H, Shen B, Chao L, Chao J. Tissue kallikrein infusion prevents cardiomyocyte apoptosis, infammation and ventricular remodeling after myocardial infarction. Regul Pept 2007; 140: 12-20.
16. Hagiwara M, Shen B, Chao L, Chao J. Kallikrein-modifed mesen-chymal stem cell implantation provides enhanced protection against acute ischemic kidney injury by inhibiting apoptosis and infamma-tion. Hum Gene Ther 2008; 19: 807-819.
17. Chao J, Zhang JJ, Lin KF, Chao L. Human kallikrein gene delivery attenuates hypertension, cardiac hypertrophy, and renal injury in Dahl salt-sensitive rats. Hum Gene Ther 1998; 9: 21-31.
18. Deuse T, Peter C, Fedak PW, Doyle T, Reichenspurner H, Zimmermann WH, et al. Hepatocyte growth factor or vascular endothelial growth factor gene transfer maximizes mesenchymal stem cell-based myo-cardial salvage after acute myocardial infarction. Circulation 2009; 120: S247-S254.
19. Pfeffer MA, Pfeffer JM, Steinberg C, Finn P. Survival after an experimental myocardial infarction: Benefcial effects of long-term therapy with captopril. Circulation 1985; 72: 406-412.
20. Yao YY, Yin H, Shen B, Smith RS Jr, Liu Y, Gao L, et al. Tissue kallikrein promotes neovascularization and improves cardiac function by the Akt-glycogen synthase kinase-3beta pathway. Cardiovasc Res 2008; 80: 354-364.
21. Kido M, Du L, Sullivan CC, Li X, Deutsch R, Jamieson SW, et al. Hypoxia-inducible factor 1-alpha reduces infarction and attenuates progression of cardiac dysfunction after myocardial infarction in the mouse. J Am Coll Cardiol 2005; 46: 2116-2124.
22. Siwik DA, Pagano PJ, Colucci WS. Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac f-broblasts. Am J Physiol Cell Physiol 2001; 280: C53-C60.
23. Pittenger MF, Martin BJ. Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res 2004; 95: 9-20.
24. Brazil DP, Park J, Hemmings BA. PKB binding proteins: Getting in on the Akt. Cell 2002; 111: 293-303.
25. Fujio Y, Nguyen T, Wencker D, Kitsis RN, Walsh K. Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation 2000; 101: 660-667.
26. Cheng XW, Huang Z, Kuzuya M, Okumura K, Murohara T. Cysteine protease cathepsins in atherosclerosis-based vascular disease and its complications. Hypertension 2011; 58: 978-986.
27. Cheng XW, Shi GP, Kuzuya M, Sasaki T, Okumura K, Murohara T. Role for cysteine protease cathepsins in heart disease. Circulation 2012; 125: 1551-1562.
28. Chen XL, Zhang Q, Zhao R, Medford RM. Superoxide, H2O2, and iron are required for TNF-alpha-induced MCP-1 gene expression in endothelial cells: Role of Rac1 and NADPH oxidase. Am J Physiol Heart Circ Physiol 2004; 286: H1001-H1007.
29. De Keulenaer GW, Ushio-Fukai M, Yin Q, Chung AB, Lyons PR, Ishizaka N, et al. Convergence of redox-sensitive and mitogen-acti-vated protein kinase signaling pathways in tumor necrosis factor-alpha-mediated monocyte chemoattractant protein-1 induction in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2000; 20: 385-391.
30. Kuldo JM, Westra J, Asgeirsdóttir SA, Kok RJ, Oosterhuis K, Rots MG, et al. Differential effects of NF-kappaB and p38 MAPK inhibitors and combinations thereof on TNF-alpha- and IL-1beta-induced proinfammatory status of endothelial cells in vitro. Am J Physiol Cell Physiol 2005; 289: C1229-C1239.
31. Frangogiannis NG, Smith CW, Entman ML. The infammatory response in myocardial infarction. Cardiovasc Res 2002; 53: 31-47.
32. Gorman RC, Jackson BM, Burdick JA, Gorman JH. Infarct restraint to limit adverse ventricular remodeling. J Cardiovasc Transl Res 2011; 4: 73-81.
33. Liu YH, Yang XP, Sharov VG, Nass O, Sabbah HN, Peterson E, et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure: Role of kinins and angiotensin II type 2 receptors. J Clin Invest 1997; 99: 1926-1935.
34. Tschesche H, Knauper V, Kramer S, Michaelis J, Oberhoff R, Reinke H. Latent collagenase and gelatinase from human neutrophils and their activation. Matrix Suppl 1992; 1: 245-255.
35. Koch M, Spillmann F, Dendorfer A, Westermann D, Altmann C, Sahabi M, et al. Cardiac function and remodeling is attenuated in transgenic rats expressing the human kallikrein-1 gene after myocardial infarction. Eur J Pharmacol 2006; 550: 143-148.